Journal article
Selective laser trabeculoplasty versus topical medication as initial glaucoma treatment: The glaucoma initial treatment study randomised clinical trial
GS Ang, EK Fenwick, M Constantinou, ATL Gan, REK Man, RJ Casson, EA Finkelstein, I Goldberg, PR Healey, K Pesudovs, S Sanmugasundram, J Xie, R Mcintosh, J Jackson, AP Wells, A White, K Martin, MJ Walland, JG Crowston, EL Lamoureux
British Journal of Ophthalmology | BMJ PUBLISHING GROUP | Published : 2020
Abstract
Background/Aims To determine if selective laser trabeculoplasty (SLT) is superior to topical medication as a first-line treatment for glaucoma on quality of life (QoL) and clinical outcomes. Methods In this international, longitudinal, multisite randomised controlled trial, treatment naïve mild-to-moderate primary open angle or exfoliation glaucoma patients were randomised 1:1 to SLT or topical medication. Glaucoma-specific QoL (primary outcome) was measured using the Glaucoma Outcomes Assessment Tool (GOAT; 342 items, 12 domains). Secondary outcomes included rate of successful intraocular pressure (IOP) reduction (25% reduction from baseline) and presence of ocular surface disease including..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
This Randomised Controlled Trial was funded by a Project Grant from the Australian National Health and Medical Research Council (NHMRC #1009844-EL as PI). CERA receives operational infrastructure support from the Victorian Government. Last and corresponding author ELL was funded by a NHMRC Research Fellowship (#1045280) and co-last author JGC was funded by an NHMRC Practitioner Fellowship (#529915) and by the Dorothy Adele Edols Charitable Trust. Co-main author EKF was funded by an NHMRC Early Career Fellowship (#1072987).